Literature DB >> 15138998

Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.

Idoya Lahortiga1, Iria Vázquez, Xabier Agirre, María J Larrayoz, José L Vizmanos, Alessandro Gozzetti, María J Calasanz, María D Odero.   

Abstract

Patients with 3q21q26 rearrangements seem to share similar clinicopathologic features and a common molecular mechanism, leading to myelodysplasia or acute myeloid leukemia (AML). The ectopic expression of EVI1 (3q26) has been implicated in the dysplasia that characterizes this subset of myeloid neoplasias. However, lack of EVI1 expression has been reported in several cases, and overexpression of EVI1 was detected in 9% of AML cases without 3q26 abnormalities. We report the molecular characterization of seven patients with inv(3)(q21q26), t(3;3)(q21;q26) or related abnormalities. EVI1 expression was detected in only one case, and thus ectopic expression of this gene failed to explain all of these cases. GATA2 (3q21) was found to be overexpressed in 5 of the 7 patients. GATA2 is highly expressed in stem cells, and its expression dramatically decreases when erythroid and megakaryocytic differentiation proceeds. No mutations in GATA1 were found in any patient, excluding loss of function of GATA1 as the cause of GATA2 overexpression. We report finding molecular heterogeneity in patients with 3q21q26 rearrangements in both breakpoints and in the expression pattern of the genes near these breakpoints. Our data suggest that a unique mechanism is not likely to be involved in 3q21q26 rearrangements. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15138998     DOI: 10.1002/gcc.20033

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

Review 1.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

2.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

3.  Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Authors:  Heesun J Rogers; James W Vardiman; John Anastasi; Gordana Raca; Natasha M Savage; Athena M Cherry; Daniel Arber; Erika Moore; Jennifer J D Morrissette; Adam Bagg; Yen-Chun Liu; Susan Mathew; Attilio Orazi; Pei Lin; Sa A Wang; Carlos E Bueso-Ramos; Kathryn Foucar; Robert P Hasserjian; Ramon V Tiu; Matthew Karafa; Eric D Hsi
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

4.  Loss of c-Kit and bone marrow failure upon conditional removal of the GATA-2 C-terminal zinc finger domain in adult mice.

Authors:  Haiyan S Li; Jin Jin; Xiaoxuan Liang; Katie A Matatall; Ying Ma; Huiyuan Zhang; Stephen E Ullrich; Katherine Y King; Shao-Cong Sun; Stephanie S Watowich
Journal:  Eur J Haematol       Date:  2016-01-14       Impact factor: 2.997

5.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

6.  3'UTR-mediated gene silencing of the Mixed Lineage Leukemia (MLL) gene.

Authors:  Maria Gomez-Benito; Fabricio Loayza-Puch; Joachim A F Oude Vrielink; Joachim Oude Vrielink; Maria D Odero; Reuven Agami
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

7.  Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2.

Authors:  Sandra Louzada; Filomena Adega; Raquel Chaves
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

8.  3q26 chromosomal anomalies in acute myeloid leukemia: First descriptions from India.

Authors:  A Gupta; L Kumar
Journal:  J Postgrad Med       Date:  2018 Apr-Jun       Impact factor: 1.476

9.  H/ACA box small nucleolar RNA 7B acts as an oncogene and a potential prognostic biomarker in breast cancer.

Authors:  Yihan Sun; Endong Chen; Yuefeng Li; Danrong Ye; Yefeng Cai; Qingxuan Wang; Quan Li; Xiaohua Zhang
Journal:  Cancer Cell Int       Date:  2019-05-09       Impact factor: 5.722

10.  Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression.

Authors:  Jun Gu; Keyur P Patel; Bing Bai; Ching-Hua Liu; Guilin Tang; Hagop M Kantarjian; Zhenya Tang; Ronald Abraham; Rajyalakshmi Luthra; L Jeffrey Medeiros; Pei Lin; Xinyan Lu
Journal:  Mol Cytogenet       Date:  2015-08-19       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.